Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Surmodics Inc (SRDX)

Surmodics Inc (SRDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 402,167
  • Shares Outstanding, K 14,126
  • Annual Sales, $ 99,950 K
  • Annual Income, $ -27,270 K
  • 60-Month Beta 0.90
  • Price/Sales 3.97
  • Price/Cash Flow N/A
  • Price/Book 3.63
Trade SRDX with:

Options Overview Details

View History
  • Implied Volatility 60.04% ( -4.16%)
  • Historical Volatility 110.19%
  • IV Percentile 88%
  • IV Rank 81.01%
  • IV High 73.38% on 10/19/22
  • IV Low 3.19% on 08/01/22
  • Put/Call Vol Ratio 30.00
  • Today's Volume 31
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 347
  • Open Int (30-Day) 250

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.63
  • Number of Estimates 2
  • High Estimate -0.63
  • Low Estimate -0.64
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -384.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.33 +21.70%
on 01/19/23
39.17 -24.41%
on 01/10/23
-4.51 (-13.22%)
since 12/30/22
3-Month
24.33 +21.70%
on 01/19/23
39.17 -24.41%
on 01/10/23
-5.77 (-16.31%)
since 11/02/22
52-Week
24.33 +21.70%
on 01/19/23
45.85 -35.42%
on 04/21/22
-16.48 (-35.76%)
since 02/02/22

Most Recent Stories

More News
Haemonetics (HAE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HAE : 84.67 (+0.42%)
SRDX : 29.64 (+4.11%)
Surmodics to Host Virtual Annual Meeting of Shareholders

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February...

SRDX : 29.64 (+4.11%)
High Tide Inc. (HITI) Reports Q4 Loss, Tops Revenue Estimates

High Tide Inc. (HITI) delivered earnings and revenue surprises of -20% and 7.26%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

HITI : 1.6200 (+2.53%)
SRDX : 29.64 (+4.11%)
Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SRDX : 29.64 (+4.11%)
BSX : 47.97 (+0.90%)
Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2023 financial results...

SRDX : 29.64 (+4.11%)
Abbott (ABT) Q4 Earnings and Revenues Top Estimates

Abbott (ABT) delivered earnings and revenue surprises of 14.44% and 6.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ABT : 111.60 (-0.20%)
SRDX : 29.64 (+4.11%)
SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?

SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in...

SRDX : 29.64 (+4.11%)
MGNX : 5.97 (+0.34%)
Surmodics (SRDX) Stock Skids 32% on Negative Regulatory Update

Surmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA.

ABT : 111.60 (-0.20%)
MDT : 87.50 (+2.02%)
SRDX : 29.64 (+4.11%)
LNTH : 59.77 (+1.93%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or “the Company”) (NASDAQ:...

SRDX : 29.64 (+4.11%)
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or “the Company”) (NASDAQ:...

SRDX : 29.64 (+4.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Surmodics is a leading provider of medical device and In Vitro Diagnostics (IVD) technologies to the healthcare industry. It reports through two divisions: Medical Devices & IVD.'The Medical Devices segment comprises surface modification coating technologies to improve access, deliverability, and predictable...

See More

Key Turning Points

3rd Resistance Point 30.72
2nd Resistance Point 29.74
1st Resistance Point 29.11
Last Price 29.64
1st Support Level 27.50
2nd Support Level 26.52
3rd Support Level 25.89

See More

52-Week High 45.85
Fibonacci 61.8% 37.63
Fibonacci 50% 35.09
Fibonacci 38.2% 32.55
Last Price 29.64
52-Week Low 24.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar